Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

BRISBANE, Calif., April 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2013 and recent business highlights.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)InterMune reported Esbriet® (pirfenidone) revenue in the first quarter of 2013 of $10.5 million, compared with $4.9 million of Esbriet revenue in the same quarter a year earlier.  Sequentially, Esbriet revenue in the first quarter of 2013 increased 28 percent from $8.2 million in the fourth quarter of 2012.  Esbriet is InterMune's product indicated in adults for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Our launches of Esbriet in Europe continue to meet our expectations as Esbriet revenue in the first quarter of 2013 more than doubled compared with the first quarter of 2012.  Esbriet revenue has increased for six consecutive quarters since the first launch of Esbriet in Germany in September 2011, which was followed by launches in other European countries in late 2012.  With the recent successful conclusion of pricing and reimbursement processes in Italy, England and Finland, Esbriet is now priced and reimbursed in 12 of our 15 top-priority European countries.

"In January of this year, we completed an important milestone in North America: the completion of enrollment in our confirmatory Phase 3 ASCEND study, which is an important step toward making Esbriet available to IPF patients in the United States," Mr. Welch added.

Recent Business and Clinical Development Highlights

  • On January 2, 2013, Esbriet became commercially available in Canada.  Mild-to-moderate IPF affe
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
    (Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
    (Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
    Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
    ... Hard-to-transfect Cells , Dmitriy ... Kelnar, David Brown, Ambion, Inc. , ... RNA interference (RNAi) is a powerful , ... genes. It is used routinely for gene function analysis, target , ...
    ... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... , open to the air--it ... or eliminate RNase contamination. However, determining which , ...
    ... , High Quality Custom Synthesis ... Mouse, and Rat , Genomes , ... Silencer siRNA Libraries , , ... Quality Custom RNA Synthesis by Ambion Finding a highly effective ...
    Cached Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
    (Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
    (Date:7/23/2014)... do mollusks, starfish, and corals have in common? ... all calcifiersorganisms that use calcium from their environment ... stability and protection. , The July issue of ... Marine Biological Laboratory, addresses the challenges faced by ... As atmospheric carbon dioxide rises, the world,s oceans ...
    (Date:7/23/2014)... Massachusetts , July 23, 2014 ... in its new report, GLOBAL MARKETS AND TECHNOLOGIES ... related technologies is expected to grow to nearly $154.4 ... rate (CAGR) of 10.1%. The image, flow, and level ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
    Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
    ... fractures occur in the United States as a result of ... to rapid bone fusion but with limited mechanical strength often ... difficult to harvest without pain and severe morbidity. Funded by ... the Department of Chemistry, Chemical Biology and Biomedical Engineering at ...
    ... Washington two years ago launched an ambitious project harnessing the ... Foldit, turns one of the hardest problems in molecular biology ... people have now played a game that asks them to ... a princess. Results published Thursday (Aug. 5) in the ...
    ... shallow, nearshore waters, researchers from Stony Brook University ... first multi-year survey of the population of Antarctic ... near Livingston Island and discovered that nearshore waters ... waters. They also found that the nearshore waters ...
    Cached Biology News:NSF funds innovative approach to biomimetic nanofiber bone regeneration 2NSF funds innovative approach to biomimetic nanofiber bone regeneration 3Gaming for a cure: Computer gamers tackle protein folding 2Gaming for a cure: Computer gamers tackle protein folding 3Gaming for a cure: Computer gamers tackle protein folding 4First nearshore survey of Antarctic krill reveals high density, stable population in shallow waters 2
    Request Info...
    FITC~Bovine Serum Albumin...
    ... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
    , Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
    Biology Products: